Mar 6, 2020 · Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes and obesity, and reduce cardiovascular risk. Ozempic TM is a once-per-week injection …

4 days ago · Membrane Fix-a-Flat? FTD Proteins Patch Cell Surface A puncture in the plasma membrane would be a catastrophic event, if it weren’t for the swift repair job done by two families of …

Oct 23, 2025 · NLRP3 inhibitor must pass into brain to effect weight loss in obese mice. The inhibitor calms microgliosis in the hypothalamus, raising hopes for such effects in other brain areas. TN-783 …

Nov 25, 2015 · AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each …

Dec 17, 2025 · Semaglutide mildly shifted some CSF AD biomarkers, although the drug is not expected to reduce amyloid. Some scientists believe semaglutide could prevent AD or other dementias, if …

Dec 17, 2025 · Background NT-0796 is an oral, brain-penetrant inhibitor of inflammasomes that contain NLRP3, aka nod-like receptor family pyrin domain-containing protein 3. Inflammasomes are …

Empagliflozin belongs to the gliflozin class of glucose-lowering agents that includes dapagliflozin. These drugs inhibit the sodium-glucose cotransporter-2 (SGLT2), which is responsible for 90 percent of …

Dec 10, 2025 · Semaglutide Does Not Treat Alzheimer’s. Could It Prevent Dementia? Add To My AlzForum 1 comments 16 Dec 2025

Rubin R. Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331 (18):1519-1521. PubMed.

May 14, 2024 · Lixisenatide is one of four GLP-1 mimetics being tested for Alzheimer’s or Parkinson’s diseases. It is a 44-amino acid peptide closely related to exenatide (Leon et al., 2017). Lixisenatide …